Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 14 results:
[ Συντάκτης] Τίτλος Τύπος Έτος Φίλτρα: Συντάκτης is Karagiannis, Thomas [Clear All Filters]
Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis..
BMJ. 344, e1369.
(2012). Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis..
Diabetologia. 65(8), 1251-1261.
(2022). Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.
Core Evidence. Volume 12, 1 - 10.
(2017). A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes..
Diabetes Care. 47(2), 184-192.
(2024). Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy..
Core Evid. 12, 1-10.
(2017). Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial.
BMJ Open. 6(11), e012185.
(2016). Socioeconomic aspects of incretin-based therapy..
Diabetologia. 66(10), 1859-1868.
(2023). Use of the Diabetes Medication Choice Decision Aid in patients with type 2 diabetes in Greece: a cluster randomised trial..
BMJ Open. 6(11), e012185.
(2016). Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications.
Therapeutic Advances in Drug Safety. 7(2), 36 - 38.
(2016). KDIGO made 12 recommendations for managing diabetes with CKD..
Ann Intern Med. 174(3), JC26.
(2021). Most add-on therapies to metformin have similar effects on HbA1c..
Evid Based Med. 21(6), 223.
(2016). Safety of dipeptidyl peptidase 4 inhibitors: a perspective review..
Ther Adv Drug Saf. 5(3), 138-46.
(2014). GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis..
Diabetes Res Clin Pract. 174, 108737.
(2021). Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications..
Ther Adv Drug Saf. 7(2), 36-8.
(2016).